Drug Trial Radar · NCT07224581
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jan 5, 2026
Primary completion
May 2027
Study completion Jul 2028
Sponsor
- Lead sponsor
- GRIN Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Aziende Chimiche Riunite Angelini Francesco S.p.A
- First posted
- Nov 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phase 3 portion of Study RAD-GRIN-101 is a multinational, multicenter, randomized, double-blind, placebo-controlled trial followed by an open-label extension to evaluate the efficacy and safety of radiprodil in participants with GRIN-related neurodevelopmental disorder (GRIN-NDD) with a gain-of-function (GoF) genetic variant. This study will enroll two cohorts: one cohort of participants with a minimal number of countable motor seizures (with or without behavioral symptoms) (Phase 3 Cohort 1: Qualifying Seizures Cohort); and a second cohort with disease symptoms but no seizures or fewer seizures than required for the Qualifying Seizures Cohort (Phase 3 Cohort 2: Without Qualifying Seizures Auxiliary Cohort). Participants in each cohort will be randomized 1:1 to receive active drug (radiprodil) or matching placebo (Part A). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil. The placebo-controlled portion is expected to be approximately 16 weeks for participants in Phase 3 Cohort 1 and 28 weeks for participants in Phase 3 Cohort 2. The study will evaluate the effect of radiprodil on seizures and non-seizure symptoms and assess safety.
Conditions
- GRIN-related Neurodevelopmental Disorder
Interventions
RadiprodilDrug
Radiprodil oral suspension
PlaceboDrug
Placebo-to-match radiprodil oral suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): Countable motor seizures (CMS)Time frame: 12 weeks
- Part A - Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort): Adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs)Time frame: 24 weeks
- Part B - Open-Label Extension: Adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs)Time frame: Average of 2 years
Locations
61 sites in 13 countries. Site status is shown where the registry gives one.
UCLA Health - Ronald Reagan UCLA Medical Center
Los Angeles, California · Recruiting
Lucile Packard Children's Hospital
Palo Alto, California · Recruiting
Children's Hospital Colorado - Anschutz Medical Campus
Aurora, Colorado · Recruiting
Children's National Hospital
Washington D.C., District of Columbia · Recruiting
Children's National Medical Center
Washington D.C., District of Columbia · Recruiting
Nicklaus Children's Hospital
Miami, Florida · Recruiting
Pediatric Neurology and Epilepsy
Winter Park, Florida · Recruiting
Iowa Health Care - Pediatric Neurology & Specialty Clinic
Iowa City, Iowa · Recruiting
Boston Children's Hospital
Boston, Massachusetts · Recruiting
Northeast Regional Epilepsy Group (NEREG) - Hackensack
Hackensack, New Jersey · Recruiting
Columbia University - Harkness
New York, New York · Recruiting
Duke Health-Duke Children's Hospital & Health Center
Durham, North Carolina · Recruiting
Duke University Health System
Durham, North Carolina · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Not yet recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Child Neurology Consultants of Austin - South Austin
Austin, Texas · Recruiting
Children's Health Specialty Center, Dallas
Dallas, Texas · Recruiting
The University of Texas Southwestern Medical Center (UTSW)
Dallas, Texas · Recruiting
UTHealth Houston
Houston, Texas · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Queensland Children's Hospital
South Brisbane, Queensland, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
UZ Brussel
Brussels, Belgium · Recruiting
University Hospital Antwerp
Edegem, Belgium · Recruiting
Centre Hospitalier Universitaire d'Angers (CHU Angers)
Angers, France · Recruiting
CHU Angers
Angers, France · Recruiting
Hospices Civils de Lyon
Bron, France · Recruiting
Hospices Civils De Lyon
Bron, France · Recruiting
CHU de Dijon
Dijon, France · Recruiting
AP HM Hopital d'enfants de la Timone
Marseille, France · Recruiting
Hopital Necker Enfants Malades (APHP)
Paris, France · Recruiting
Hôpital Necker Enfants Malades
Paris, France · Recruiting
Hopital des Enfants ; CHU Toulouse
Toulouse, France · Recruiting
CHU Toulouse - Hôpital Purpan
Toulouse, France · Recruiting
Universitatsklinikum OWL der Universitat Bielefeld
Bielefeld, Germany · Recruiting
Universitatsmedizin Greifswald Klinik und Poliklinik fur Frauenheilkunde und Geburtshilfe
Greifswald, Germany · Recruiting
Klinik und Policlinik fur Kinder - und Jugendmedizin
Leipzig, Germany · Recruiting
Universitatsklinikum Leipzig
Leipzig, Saxony, Germany · Recruiting
IRCCS Fondazione Istituto Neurologico Nazionale Casimiro Mondino
Pavia, Italy · Recruiting
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.